Skip to main content

Table 1 Assigned Protein Identification Using LC-MS/MS

From: Proteomic analysis identifies interleukin 11 regulated plasma membrane proteins in human endometrial epithelial cells in vitro

Spot

p-value

Fold-change

Protein ID

ACC. No. (Swissprot)

Gene

Sequence coverage (%)

No. peptides identified

Mr/pI

9*

0.02

1.33

Annexin A2

P07355

ANXA2

38.6

13

38/7.56

   

Ribose-phosphate pyrophosphokinase 1

P60891

PRPS1

15.1

4

35/6.56

   

Voltage-dependent anion-selective channel protein 2

P45880

VDAC2

17.70

5

32/7.5

   

Dual specificity mitogen-activated protein kinase kinase 6

P52564

MAP2K6

11.4

3

37/7.01

14*

0.04

1.40

Flotillin-1

O75955

FLOT1

62.3

23

47/7.08

   

Alpha-enolase

P06733

ENO1

6.68

2

47/6.99

16*

0.04

-1.32

Cdc42-interacting protein 4

Q15462

TRIP10

50.6

22

69/5.55

   

78 kDa glucose-regulated protein (GRP78)

P11021

HSPA5

47.6

32

72/5.01

   

Collagen type IV alpha-3 binding protein

Q9Y5P4

COL4A3BP

20.7

9

71/5.29

   

NADH-ubiquinone oxireductase 75 kDa subunit, mitochondrial

P28331

NDUFS1

13.2

8

79/5.42

   

Stress-70 protein, mitochondrial

P38646

HSPA9

11.5

7

74/5.44

22*

0.04

-1.32

cDNA FLJ5299

A8K781

cDNA FLJ5299

47.0

17

47/5.11

   

Keratin, type II cytoskeletal 8

P05787

KRT8

46.8

25

48/5.34

   

Thioredoxin domain-containing protein 5

Q8NBS9

TXNDC5

27.3

11

48/5.37

   

Actin, cytoplasmc 1

P60709

ACTB

26.4

9

42/5.29

   

26S protease regulatory subunit 6B

P43686

PSMC4

22.7

9

47/5.09

   

Uncharacterised protein KIAA0174 (ISTI homolog)

P53990

KIAA0174

14.6

5

40/5.22

   

Eukaryotic initiation factor 4A-1

P60842

EIF4A1

16.0

5

46/5.32

   

Hsc70-interacting protein

P50502

ST13

12.5

4

41/5.18

   

Heterogenous nuclear ribonucleoprotein F

P52597

HNRNPF

19.3

4

46/5.38

  1. a Asterisk (*) denotes spots identified as containing a mixture of 2 or more proteins, or where protein isoforms cannot be distinguished based on peptides identified.
  2. P-value and fold-change obtained based on normalised spot volume between control and IL11 treated group.